AJP - GI Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Gastrointest Liver Physiol 293: G446-G452, 2007. First published May 17, 2007; doi:10.1152/ajpgi.00097.2007
0193-1857/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/2/G446    most recent
00097.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rijcken, E.
Right arrow Articles by Krieglstein, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rijcken, E.
Right arrow Articles by Krieglstein, C. F.

INFLAMMATION/IMMUNITY/MEDIATORS

PECAM-1 (CD 31) mediates transendothelial leukocyte migration in experimental colitis

Emile Rijcken, Rudolf B. Mennigen, Sebastian D. Schaefer, Mike G. Laukoetter, Christoph Anthoni, Hans-Ullrich Spiegel, Matthias Bruewer, Norbert Senninger, and Christian F. Krieglstein

Department of General Surgery, Muenster University Hospital, Germany

Submitted 23 February 2007 ; accepted in final form 16 May 2007

Transendothelial migration of circulating leukocytes into the colonic wall is a key step in the development of the inflammatory infiltrate in inflammatory bowel disease (IBD). The platelet-endothelial cell adhesion molecule-1 PECAM-1 (CD31) is expressed in the tight junction area of endothelial cells, where it is supposed to support the transmigration process. The aim of this study was to determine the role of PECAM-1 in experimental IBD and to show whether blockade of PECAM-1 has therapeutic effects. Chronic colitis was induced in female BALB/c mice by cyclic oral administration of dextran sodium sulfate (DSS) 3% (wt/vol). Expression of PECAM-1 was visualized by immunohistochemistry. In the treatment group animals received 1 mg/kg anti-PECAM-1 (2H8) ip daily starting on day 26. On day 30 leukocyte adhesion and migration was measured during N2O-isoflurane anesthesia in the distal colon by intravital microscopy. Disease activity index (DAI), histology, and MPO levels were compared with healthy and diseased controls. PECAM-1 was expressed in colitic mice. Chronic DSS colitis was characterized by a marked increase in rolling, adherent, and transmigrated leukocytes compared with healthy controls. Immunoblockade of PECAM-1 reduced leukocyte transmigration significantly and also diminished leukocyte rolling and sticking in an indirect manner. It also resulted in a significantly diminished DAI and MPO levels, as well as an amelioration of the histological inflammation score. PECAM-1 plays an important role in transendothelial leukocyte migration in DSS colitis. PECAM-1 could be a novel target for antibody-based treatment in IBD.

platelet-endothelial cell adhesion molecule-1; leukocyte transmigration; dextran sodium sulfate colitis; intravital microscopy; inflammatory bowel disease


Address for reprint requests and other correspondence: E. Rijcken, Dept. of General Surgery, Muenster Univ. Hospital, Waldeyerstrasse 1, D-48149 Muenster, Germany (e-mail: rijcken{at}uni-muenster.de)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.